Gabapentin solution

Get a Price/Quote

MOQ : 1 Kilograms

Gabapentin solution Specification

Molecular Weight
171.24 Grams (g)

Molecular Formula
C9H17NO2

Purity
99.53 %

Appearance
White to off-white crystalline solid

Usage
Gabapentin is indicated for: Management of postherpetic neuralgia in adults. Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy.

Gabapentin solution Trade Information

Minimum Order Quantity
1 Kilograms

Payment Terms
Cash in Advance (CID), Cash Advance (CA)

Supply Ability
500 Kilograms KG Per Month

Delivery Time
2-8 Week

Sample Available
Yes

Sample Policy
Sample costs shipping and taxes has to be paid by the buyer

Packaging Details
Carton and Poly Bag.

Main Export Market(s)
Western Europe, Australia, Eastern Europe, Middle East, Central America, Africa, South America, Asia, North America

Main Domestic Market
All India

About Gabapentin solution

Gabapentin solution1.0mg/mL in methanol, ampule of 1mL, certified reference materialCAS Number60142-96-3Empirical Formula (Hill Notation)C9H17NO2Molecular Weight171.24PropertiesRelated CategoriesAdditional Standards,Analytical Standards,Analytical/Chromatography,Anticonvulsants / Antiepileptics Standards,Anticonvulsants/Antiepileptics,Certified Reference Materials (CRMs),Certified Reference Materials from Cerilliant,Chromatography,Drugs & Metabolites,Gabapentin,Pharmaceutical and Drug Standards,Pharmaceuticals, Illicit Drugs & AlcoholInChI Key UGJMXCAKCUNAIE-UHFFFAOYSA-Npackaging ampule of 1mLconcentration 1.0mg/mL in methanolformat single component solutionstorage temp. 20C

FAQs of Gabapentin solution:

Q: What is the appearance of Gabapentin Solution?

A: Gabapentin Solution is a white to off-white crystalline solid.

Q: What are the primary uses of Gabapentin Solution?

A: Gabapentin Solution is indicated for the management of postherpetic neuralgia in adults and as an adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy.